Search:   [Advanced]

Showing drug card for Dextrothyroxine (DB00509)

Legend: drug field target field enzyme field

for All Approved Biotech Experimental Illicit Nutraceutical Small Molecule Withdrawn drugs

Version	2.5
Creation Date	2005-06-13 13:24:05
Update Date	2009-04-16 16:47:45
Primary Accession Number	DB00509
Secondary Accession Number	APRD00911
Name	Dextrothyroxine
Drug Type	Approved Small Molecule
Description	The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine which exerts a broad spectrum of stimulatory effects on cell metabolism. [PubChem]
Synonyms	Not Available
Brand Names	Choloxin
Brand Mixtures	Not Available
Chemical IUPAC Name	2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid
Chemical Formula	C15H11I4NO4
Chemical Structure
CAS Registry Number	51-49-0
InChI Identifier	InChI=1/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/f/h22H
InChI Key	XUIIKFGFIJCVMT-QWOVJGMICH
KEGG Drug	Not Available
KEGG Compound	Not Available
PubChem Compound	853
PubChem Substance	93081
ChEBI ID	30659
PharmGKB ID	PA449277
HET ID	Not Available
GenBank ID	Not Available
Drug ID Number [DIN]	02170299
RxList Link	Not Available
PDRhealth Link	Not Available
Wikipedia Link	http://en.wikipedia.org/wiki/Dextrothyroxine
FDA Label	Not Available
Material Safety Data Sheet (MSDS)	Show PDF
Synthesis Reference	Not Available
Average Molecular Weight	776.8700
Monoisotopic Molecular Weight	776.6867
State	Solid
Melting Point	235 - 236 oC
Experimental Water Solubility	Not Available Source: PhysProp
Predicted Water Solubility	8.98e-03 mg/mL Calculated using ALOGPS
Experimental LogP/Hydrophobicity	4 Source: PhysProp
Predicted LogP	1.15 Calculated using ALOGPS
Experimental LogS	Not Available
Predicted LogS	-4.94 Calculated using ALOGPS
Experimental Caco2 Permeability	Not Available
pKa/Isoelectric Point	Not Available
Mass Spectrum	Not Available
MOL File	Show | Download
SDF File	Show | Download
PDB File	Show | Download
2D Structure
3D Structure
Experimental PDB ID	Not Available
Isomeric SMILES	N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
Canonical SMILES	NC(CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(O)=O
Drug Category	Antihyperlipidemics
ATC Codes	C10AX01 H03AA01
AHFS Codes	68:36.04
Indication	Used to lower high cholesterol levels in the blood.
Pharmacology	Dextrothyroxine, the dextrorotary isomer of the synthetic thyroxine, is a antihyperlipidemic.
Mechanism of Action	Dextrothyroxine is a antihyperlipidemic. The mechanism of action is not completely understood, but dextrothyroxine apparently acts in the liver to stimulate formation of low-density lipoprotein (LDL) and, to a much greater extent, to increase catabolism of LDL. This leads to increased excretion of cholesterol and bile acids via the biliary route into the feces, with a resulting reduction in serum cholesterol and LDL. Dextrothyroxine has no significant effect on high-density lipoproteins (HDL).
Absorption	Not Available
Toxicity	Symptoms of dextrothyroxine overdose are unknown.
Protein Binding	Not Available
Biotransformation	Not Available
Half Life	Not Available
Dosage Forms	Form Route Powder, for solution Intravenous Tablet Oral
Patient Information	Not Available
Contraindications	Not Available
Interactions	Not Available
Drug Interactions	Drug Interaction Acenocoumarol Thyroid hormones increase the anticoagulant effect Anisindione Thyroid hormones increase the anticoagulant effect Dicumarol Thyroid hormones increase the anticoagulant effect Digoxin The thyroid hormone decreases the effect of digoxin Warfarin Thyroid hormones increase the anticoagulant effect
Food Interactions	Take without regard to meals.
Pathways	Not Available
General References	Drugs.com Wikipedia
Organisms Affected	Humans and other mammals

This project is supported by Genome Alberta & Genome Canada, a not-for-profit organization that is leading Canada's national genomics strategy with $600 million in funding from the federal government. This project is also supported in part by GenomeQuest, Inc., an enterprise genomic information company serving the life science community.